CoChat

Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol

The DOI matches its Crossref record; 136 of the 137 references it cites were found in a registry or an index.

Abstract

Notwithstanding the effectiveness of lowering LDL cholesterol, residual CVD risk remains in high-risk populations, including patients with diabetes, likely contributed to by non-LDL lipid abnormalities. In this Perspectives in Diabetes article, we emphasize that changing demographics and lifestyles over the past few decades have resulted in an epidemic of the “atherogenic dyslipidemia complex,” the main features of which include hypertriglyceridemia, low HDL cholesterol levels, qualitative changes in LDL particles, accumulation of remnant lipoproteins, and postprandial hyperlipidemia. We briefly review the underlying pathophysiology of this form of dyslipidemia, in particular its association with insulin resistance, obesity, and type 2 diabetes, and the marked atherogenicity of this condition. We explain the failure of existing classes of therapeutic agents such as fibrates, niacin, and cholesteryl ester transfer protein inhibitors that are known to modify components of the atherogenic dyslipidemia complex. Finally, we discuss targeted repurposing of existing therapies and review promising new therapeutic strategies to modify the atherogenic dyslipidemia complex. We postulate that targeting the central abnormality of the atherogenic dyslipidemia complex, the elevation of triglyceride-rich lipoprotein particles, represents a new frontier in CVD prevention and is likely to prove the most effective strategy in correcting most aspects of the atherogenic dyslipidemia complex, thereby preventing CVD events.

Overview

Integrity signals

Registry

Crossref · 10.2337/db16-0046

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 136 references

Cited by

Items 201–211 of 211

Metadata

Authors
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F.
Affiliations
  • University of Toronto (CA)
  • Western University (CA)
Corresponding author
Lewis, Gary F.
Venue
Diabetes
Published
2016-06-13
Volume
65
Issue
7
Pages
1767-1778
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2472281584
Cited by
212
References
137
Citations by year
2026: 6 · 2025: 21 · 2024: 20 · 2023: 20 · 2022: 34 · 2021: 35 · 2020: 23 · 2019: 25 · 2018: 13 · 2017: 12 · 2016: 2
FWCI
3.44
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes (publishedVersion)
  • PubMed (publishedVersion)
Funders
Canadian Institutes of Health Research (MOP‑79533), MOP13430, MOP-43839)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
residual cardiovascular risk, hypertriglyceridemia, low HDL cholesterol, remnant lipoproteins, postprandial lipemia, triglyceride-rich lipoproteins, insulin resistance, type 2 diabetes, obesity, fibrates, nicotinic acid, cholesteryl ester transfer protein inhibitors, drug repurposing, cardiovascular disease prevention
MeSH terms
Hypolipidemic Agents, Cardiovascular Diseases, Humans, Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.